Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
JAMA Oncology|August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label StudyThomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Clinical Genitourinary Cancer|March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell CarcinomaGuillermo De Velasco, Wanling Xie, Frede Donskov, et al.
European Urology|December 20, 2014
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapiesNils Kroeger, Allan J Pantuck, J Connor Wells, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
The Journal of Urology|July 18, 2018
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaGuru P Sonpavde, Luigi Mariani, Salvatore Lo Vullo, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
JAMA Oncology|August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label StudyThomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Clinical Genitourinary Cancer|March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell CarcinomaGuillermo De Velasco, Wanling Xie, Frede Donskov, et al.
European Urology|December 20, 2014
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapiesNils Kroeger, Allan J Pantuck, J Connor Wells, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
The Journal of Urology|July 18, 2018
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaGuru P Sonpavde, Luigi Mariani, Salvatore Lo Vullo, et al.
Pageof 16